Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | PREP | P48147 | 4/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25881059 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL14098540 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25889563 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5100398 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL14098541 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5100393 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2535821 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20241612 | 0.94 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30297856 | 0.86 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25889745 | 0.86 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161281-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025093870-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-08 | — | — | WO | disclosed |
| CN-119095845-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4469155-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023141323-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-11072602-B2 | Antidiabetic heterocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | CHRM2 4861/4885CHRM1 4882/4885CHRM3 4821/4885 |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | CHRM2 249/4885CHRM1 23/4885CHRM3 1041/4885 |
| US-11072602-B2 | Antidiabetic heterocyclic compounds | GPR119, GLP1R, GPR65 | CHRM2 816/4885CHRM1 1214/4885CHRM3 760/4885 |
| US-20250161281-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | CHRM2 4528/4885CHRM1 4644/4885CHRM3 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.